Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 5/20 | 0.52 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.51 |
| ▸ | NEK2 | P51955 | 1/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.47 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | ATR | Q13535 | 4/20 | 0.47 |
| ▸ | PRKDC | P78527 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.46 |
| ▸ | LDHA | P00338 | 1/20 | 0.45 |
| ▸ | LDHB | P07195 | 1/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2930299 | 0.87 | MAPK1 (0.54) | MAPK1ACVR1NEK2CHEK1ATR | |
| SCHEMBL2930301 | 0.87 | MAPK1 (0.54) | MAPK1ACVR1NEK2CHEK1ATR | |
| SCHEMBL2931488 | 0.81 | NEK2 (0.64) | NEK2CHEK1ATRPRKDCATM | |
| SCHEMBL2930631 | 0.81 | ACVR2A (0.57) | ACVR1AURKACHEK1ATRPRKDC | |
| SCHEMBL6696482 | 0.80 | PIK3CG (0.55) | MAPK1NEK2CHEK1ATRPRKDC | |
| SCHEMBL2936756 | 0.79 | ATR (0.62) | ATR | |
| SCHEMBL15201514 | 0.77 | ATR (0.58) | MAPK1NEK2CHEK1ATRPRKDC | |
| SCHEMBL2934243 | 0.75 | KCNH2 (0.63) | CHEK1ATRPRKDCKCNH2 | |
| SCHEMBL15201610 | 0.75 | ATR (0.64) | MAPK1NEK2CHEK1ATRPRKDC | |
| SCHEMBL934795 | 0.75 | ADORA1 (0.56) | ATRPRKDCATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044051-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB PUBL (SE) | 2010-01-27 | — | — | EP | disclosed |
| EP-2044051-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB PUBL (SE) | 2010-01-27 | — | — | EP | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
| WO-2007147874-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB (PUBL) (SE) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039450-A1 | Compounds | NEK2, CSNK2A3, CSNK2A1 | MAPK1 255/4885ACVR1 2828/4885NEK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.